BBC Inside Science cover image

Killer smog

BBC Inside Science

00:00

The Effect of Lecanamab on Alzheimer's Disease

The effect of Lecanamab is statistically significant, but its clinical significance seems to be quite small. If the effect is sustained after the 18 months trial period, patients on this drug have to come up every two weeks for infusions. We can't give people a drug that targets amyloid without knowing they've got amyloid protein in their brains. So before giving the drug, you need tests that currently 99% of patients don't get. There is a mountain to climb in terms of developing the services that can really deliver these treatments to the right patients early in the course of Alzheimer's disease.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app